Astrana Health (NASDAQ:ASTH – Get Free Report) was upgraded by equities research analysts at Truist Financial to a “buy” rating in a research note issued to investors on Thursday, Stock Target Advisor reports. The firm currently has a $50.00 price target on the stock. Truist Financial’s price target points to a potential upside of 30.89% from the stock’s current price.
Other analysts also recently issued research reports about the company. Baird R W raised Astrana Health to a “strong-buy” rating in a research note on Thursday, May 30th. Robert W. Baird began coverage on Astrana Health in a research report on Thursday, May 30th. They set an “outperform” rating and a $54.00 price target on the stock. Finally, Stifel Nicolaus boosted their price objective on Astrana Health from $45.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $50.50.
Read Our Latest Research Report on ASTH
Astrana Health Trading Down 0.4 %
Shares of ASTH opened at $38.20 on Thursday. The company has a market capitalization of $2.14 billion, a PE ratio of 28.94, a P/E/G ratio of 1.41 and a beta of 1.16. Astrana Health has a 1 year low of $28.86 and a 1 year high of $45.71. The stock’s 50-day moving average is $39.84. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.52 and a current ratio of 1.52.
Astrana Health (NASDAQ:ASTH – Get Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). Astrana Health had a return on equity of 10.22% and a net margin of 4.29%. The firm had revenue of $404.36 million for the quarter, compared to the consensus estimate of $413.84 million. During the same period in the previous year, the business earned $0.42 EPS. The firm’s revenue was up 19.9% compared to the same quarter last year. As a group, equities analysts forecast that Astrana Health will post 1.41 EPS for the current year.
Astrana Health Company Profile
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Recommended Stories
Receive News & Ratings for Astrana Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Astrana Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
